SARS‐CoV‐2 vaccination appears to be safe in antiphospholipid antibody syndrome: Comment on evaluation of patients with antiphospholipid syndrome subsequently COVID‐19 vaccinations
International Journal of Rheumatic Diseases · 2023
DOI: 10.1111/1756-185x.14727 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2023. Verfasst von Kritika Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
All the analyses performed for this article have been reported in the main text. Data pertaining to the article shall be shared on reasonable request to the corresponding author (Durga Prasanna Misra, [email protected]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.
ORCID-Profile: Kritika Singh, Durga Prasanna Misra
Zitieren
APA
Singh, K., & Misra, D. P. (2023). SARS‐CoV‐2 vaccination appears to be safe in antiphospholipid antibody syndrome: Comment on evaluation of patients with antiphospholipid syndrome subsequently COVID‐19 vaccinations. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14727
Vancouver
Singh K, Misra DP. SARS‐CoV‐2 vaccination appears to be safe in antiphospholipid antibody syndrome: Comment on evaluation of patients with antiphospholipid syndrome subsequently COVID‐19 vaccinations. International Journal of Rheumatic Diseases. 2023. doi:10.1111/1756-185x.14727
BibTeX
@article{Singh2023,
author = {Singh, Kritika and Misra, Durga Prasanna},
title = {SARS‐CoV‐2 vaccination appears to be safe in antiphospholipid antibody syndrome: Comment on evaluation of patients with antiphospholipid syndrome subsequently COVID‐19 vaccinations},
journal = {International Journal of Rheumatic Diseases},
year = {2023},
doi = {10.1111/1756-185x.14727}
}
EUVIMED